## Abstract Bradykinin (BK) is a potent short‐lived effector belonging to a class of peptides known as kinins. It participates in inflammatory and vascular regulation and processes including angioedema, tissue permeability, vascular dilation, and smooth muscle contraction. BK exerts its biological
Co-regulation of B-Myb expression by E2F1 and EGF receptor
✍ Scribed by Norihisa Hanada; Hui-Wen Lo; Chi-Ping Day; Yong Pan; Yusuke Nakajima; Mien-Chie Hung
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 233 KB
- Volume
- 45
- Category
- Article
- ISSN
- 0899-1987
- DOI
- 10.1002/mc.20147
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is frequently over‐expressed in human cancers and is associated with tumorigenesis, and increased tumor proliferation and progression. Also found in breast tumors with high levels is B‐Myb, a transcription factor whose expression is activated by E2F1/3 at the late G~1~ phase and the level is sustained through the S phase. Recent reports suggest a casual correlation between EGFR and B‐Myb expression in primary breast carcinomas. However, the mechanism for such co‐expression remains un‐investigated. Here, we report that EGFR is important for B‐Myb expression and the underlying mechanism involves cooperated effects from EGFR and E2F1. EGF stimulation and forced expression of EGFR significantly increase B‐Myb gene activity and such increase occurs in the G~1~ phase. EGF‐induced B‐Myb expression was not significantly suppressed following inhibition of PI‐3K and ERK, two major EGFR downstream pathways. In contrast, we observed EGF‐induced in vivo association of nuclear EGFR to the B‐Myb promoter and the association is only detected at the G~1~/S phase and is abolished by EGFR kinase inhibitor. As EGFR lacks DNA‐binding domain but contains transactivational activity and E2F1 activates B‐Myb expression in the G~1~/S phase, we further reasoned that nuclear EGFR might cooperate with E2F1 leading to activation of B‐Myb. Indeed, we found that EGFR co‐immunoprecipitated with E2F1 in an EGF‐dependent manner and that EGF activated in vivo binding of E2F1 to the B‐Myb promoter. Consistently, forced expression of both EGFR and E2F1 in EGFR‐null CHO cells greatly enhanced B‐Myb promoter activity, compared to the vector control and expression of EGFR or E2F1 alone. Promoter mutagenesis studies showed that EGF‐induced activation of B‐Myb promoter required both E2F and EGFR target sites. In summary, our data suggest that deregulated EGFR signaling pathway facilitate tumor cell proliferation partly via EGFR interaction with E2F1 and subsequent activation of B‐Myb gene expression. © 2005 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract The insulin receptor substrate‐1 (IRS‐1), a docking protein of the type 1 insulin‐like growth factor receptor (IGF‐IR) plays a significant role in cell proliferation and differentiation. The expression of IRS‐1 is down‐regulated in mouse embryo fibroblasts (MEFs) with a deletion of cave
The adhesion of tumor cells to various extracellular matrix (ECM) proteins is influenced by epidermal growth factor (EGF). Maximal effects are obtained at low EGF concentrations, at which mostly the cytoskeleton-associated high-affinity EGF receptors (EGFRs) are saturated. Tumor cells expressing EGF
## Abstract ## Objective To evaluate the effects of LG100268 (LG268), a synthetic ligand for the nuclear hormone receptor retinoid X receptor, on the expression of matrix metalloproteinase 1 (MMP‐1) and MMP‐13 induced by proinflammatory cytokines in a chondrocyte model. ## Methods SW‐1353 human